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Abstract
The data set simulated for Genetic Analysis Workshop 17 was designed to mimic a subset of data that might be
produced in a full exome screen for a complex disorder and related risk factors in order to permit workshop
participants to investigate issues of study design and statistical genetic analysis. Real sequence data from the 1000
Genomes Project formed the basis for simulating a common disease trait with a prevalence of 30% and three
related quantitative risk factors in a sample of 697 unrelated individuals and a second sample of 697 individuals in
large, extended pedigrees. Called genotypes for 24,487 autosomal markers assigned to 3,205 genes and simulated
affection status, quantitative traits, age, sex, pedigree relationships, and cigarette smoking were provided to
workshop participants. The simulating model included both common and rare variants with minor allele
frequencies ranging from 0.07% to 25.8% and a wide range of effect sizes for these variants. Genotype-smoking
interaction effects were included for variants in one gene. Functional variants were concentrated in genes selected
from specific biological pathways and were selected on the basis of the predicted deleteriousness of the coding
change. For each sample, unrelated individuals and family, 200 replicates of the phenotypes were simulated.
Background
The state of the science for localization and identifica-
tion of genes that influence common complex diseases
has changed rapidly over the past 20 years. As labora-
tory costs continue to fall with the development of
more efficient high-throughput techniques, the field is
quickly proceeding toward studies that make use of gen-
ome-wide sequence data. There is as yet no consensus
on optimal, or even appropriate, statistical genetic
approaches for analyzing exome sequence data, and few
investigators have had experience analyzing such data
sets. This was the motivation for the Genetic Analysis
Workshop 17 (GAW17) “mini-exome” data set. The
GAW17 data set is a hybrid of simulated and real data.
Real exome sequence data from the 1000 Genomes Pro-
ject were used as the basis for simulating a common
complex disease and related quantitative risk factors.
Two different study designs were simulated, unrelated
individuals and large families, each with the same sam-
ple size.
1000 Genomes Project
The 1000 Genomes Project (http://www.1000genomes.
org) is designed to survey genetic variation at the
sequence level across multiple human population
groups. It includes individuals of European, East Asian,
South Asian, West African, and American Indian ances-
try. Three pilot projects for the 1000 Genomes Project
were completed in 2010: low-fold genome-wide sequen-
cing of 179 individuals, higher fold sequencing of two
parent-child trios, and exonic sequencing in 697 indivi-
duals [1]. Publicly available exon sequence data from the
1000 Genomes Project were used to provide a realistic
pattern of number and frequency of single-nucleotide
polymorphisms (SNPs), including cross-population var-
iation and linkage disequilibrium between sites, for the
GAW17 simulations.
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Genotype calling
SNP genotypes were obtained from the sequence align-
ment files provided by the 1000 Genomes Project for
their pilot3 study. When the GAW17 data set was gen-
erated, the 1000 Genomes Project had not yet posted
processed calls of these genotypes for each individual.
Thus the UnifiedGenotyper method from the Genome
Analysis Toolkit (GATK) package [2] was used for the
detection of SNPs and for the calling of SNP genotypes.
A male human genome based on National Center for
Biotechnology Information reference sequence 36
(RefSeq36) human genome release (human_b36_male.
fasta.gz) was used as the reference genome sequence for
both male and female alignments.
The UnifiedGenotyper method was run twice on the
alignment files. The first time it was allowed to scan
freely through the alignments to search for variation
against the reference sequence to be considered as SNP
candidates. Genotypes that were not homozygous for
the reference base allele were called for the candidate
SNPs detected. Because of time and technical con-
straints, GAW17 SNPs were chosen to be the subset of
candidate SNP genotypes that were called from an align-
ment of 10 or more sequencing reads. During the sec-
ond run, genotypes, including those homozygous for the
reference base, were called only for the subset of SNPs
selected in the first run.
This procedure had the advantages of being fast, cor-
rectly calling most of the true common SNP variants, gen-
erating a large volume of rare SNP variants, and
producing a genotype matrix with few missing genotypes
to simplify downstream preparation of the simulated data
set. However, it was not meant to detect the true natural
variation present in the 1000 Genomes Project. Thus there
were more rare SNPs in the GAW17 data set than those
described in the 1000 Genomes Project Consortium ana-
lyses of their own pilot data sets [1]. The enrichment of
rare variants in the GAW17 data set was caused in part by
artifacts introduced by, for example, lack of filtering.
The 1000 Genomes Project genotypes were not
phased, and some genotypes were missing as a result of
i n c o m p l e t es e q u e n c ec o v e r a g ei ns o m ei n d i v i d u a l s .W e
used the program fastPHASE [http://depts.washington.
edu/uwc4c/express-licenses/assets/fastphase/] to infer
missing genotypes and haplotypic phase. In the family
data set (described later), we used the program CHRSIM
[3] to drop the phased founder haplotypes throughout
the rest of the pedigree. Recombination was taken into
account, with a single obligate crossover event occurring
on each chromosome.
As noted, the GAW17 genotypes differ from the offi-
cial 1000 Genomes Project called genotypes for the
same individuals because of differing approaches to gen-
otype calling, inclusion or exclusion of regions of low-
fold coverage, and the inclusion of the imputed geno-
types in the GAW17 data set. Imputed genotypes were
n o ti d e n t i f i e da ss u c hi nt h ed i s t r i b u t e dd a t aa n dw e r e
treated as equally “real” as called genotypes in the phe-
notype simulations. These choices were motivated by a
focus on designing a data set that would be useful for
developing methods related to gene localization, identifi-
cation, and characterization, with the 1000 Genomes
Project data primarily serving as a source of sequence
data with realistic patterns of SNP distribution, allele
frequency, population variation, and linkage disequili-
brium. However, these decisions limited the utility of
the GAW17 data for population genetic analyses or for
examination of effects of genotype calling or data clean-
ing on gene finding.
Distributed genotype data
The called genotype data distributed for GAW17
included the inferred genotypes, such that all individuals
had genotypes for all base-pair positions, and phenotypes
were simulated on the basis of these data. Markers were
numbered sequentially on each chromosome and were
labeled C#S# (e.g., C1S254 is the 254th SNP on chromo-
some 1); marker locations were recorded as RefSeq36
base-pair coordinates. The 24,487 autosomal SNPs
detected in genotype calling were, for purposes of the
simulation, assigned to 3,205 genes based on the first
intersection found of the marker location and the base-
pair coordinates of all genes obtained from RefSeq36
annotations. SNPs that overlapped multiple genes were
assigned to only one of those genes. There were 1 to 231
SNPs per gene (mean = 7.64, SD = 14.00). Of the SNPs,
9,433 (38.4%) were private variants, occurring once in the
set of 697 unrelated individuals. Multiple private variants
carried by the same individual resulted in SNPs with
identical genotypes, including a SNP in the KDR gene
that was designated as functional in the phenotype simu-
lations which had identical genotypes to multiple non-
functional SNPs. Relatively few of the variants were
common; 74% had minor allele frequency (MAF) ≤ 0.01
and only 12.8% had MAF ≥ 0.05 (Figure 1). The median
MAF was 0.002, that is, three copies of the minor allele
in the sample of 697 unrelated individuals.
Unrelated individuals and pedigree samples
Two disparate sampling designs were used in the con-
struction of the simulated data. One sample consisted of
697 unrelated individuals, each of whom corresponded
to an individual from the 1000 Genomes Project data.
The 1000 Genomes Project subjects whose data were
used came from the CEPH (European-descent residents
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nese (n = 109), Japanese (n = 72), Luhya (n = 108), Tus-
can (n = 66), and Yoruban (n = 112) population groups.
The second sample configuration used in GAW17 simu-
lations consisted of 697 individuals in 8 extended
families with the genotypes for the 202 pedigree foun-
ders being taken from the 1000 Genomes Project data.
The founders of the pedigrees were chosen at random
from the unrelated individuals sample and included 12
CEPH, 18 Denver Chinese, 19 Han Chinese, 28 Japa-
nese, 50 Luhya, 66 Tuscan, and 9 Yoruban samples.
Because of a computational error, the genotypes of pedi-
gree founders were merged incorrectly across files,
resulting in an incomplete match between the genotypes
of the pedigree founders and the corresponding indivi-
dual from the unrelated individuals sample. This
affected a small proportion of genotypes (7%) but
impacted all pedigree founders. Approximately one-third
of the SNPs were unaffected, and for the two-thirds that
had substitutions, most had only one or two founders
with altered genotypes. Pedigree configurations were
adapted from the pedigrees used for simulated data in
Genetic Analysis Workshops 10 and 12 [4,5] and
included four generations and relatives as distant as sec-
ond cousins. The data set was designed such that all
family members had genotype and phenotype data avail-
able with no missing or unexamined relatives.
Because the pedigree founders were a subset of the
unrelated individuals, genetic diversity was restricted in
the families compared to the unrelated individuals sam-
ple. Of the 24,487 variant sites identified in the unre-
lated individuals sample, 10,703 were monomorphic in
the family sample with only one allele appearing. On the
other hand, some variants that were present in single
copies or at low frequency in the unrelated individuals
sample appeared many times in the family sample,
b e c a u s et h e yw e r et r a n s m i t t e db yaf o u n d e rw i t h
numerous descendants. For example, C6S2981, which
was designated as functional in the phenotype simula-
tions, was present in 3 copies in the unrelated indivi-
duals sample and in 46 copies in the family sample.
C4S4935, also designated as functional in the simula-
tions, was present in a single copy in the unrelated indi-
viduals sample but in 31 copies in the pedigree sample.
There are 327 males and 370 females in the unrelated
individuals data set, which preserved the listed sex for
each of the 1000 Genomes Project samples. The family
set included 346 males and 351 females. Pedigree foun-
ders were allowed to have a different sex from the unre-
lated individuals whose genotypes they shared. However,
only autosomal markers were used in the GAW17 simu-
lations (i.e., X and Y data were not included). Assigned
ages were matched across the family and unrelated indi-
viduals data sets and ranged from 16 to 91 years, with a
mean of 41.8 years.
For the family data set, fully informative markers were
generated at each gene (recombination was not allowed
within genes) and used to compute identical-by-descent
(IBD) allele sharing at each gene location under the
rationale that family-based data sets were likely to have
previous short tandem repeat (STR) or high-density
SNP genotyping that could be used to estimate the IBD
allele sharing. These IBD matrices were provided as part
of the GAW17 data set.
Phenotype model
A common disease, with a prevalence of 30%, was simu-
lated along with three related quantitative risk factors,
Q1, Q2, and Q4. Smoking status (prevalence 25%) was
also simulated. Phenotype simulations were performed
multiple times to generate 200 replicates of the unre-
lated individuals and pedigree data sets. Note that the
genotype data remained constant across replicates, as
did age, sex, and pedigree configuration.
Knowledge about biological pathways and statistical
predictions regarding the potential deleteriousness of
coding variants was used in designing the simulation
model. Pathways for gene enrichment were selected from
the publicly available Kyoto Encyclopedia of Genes and
Genomes (KEGG) database (http://www.genome.jp/kegg/)
and the proprietary software Ingenuity Pathways Analysis
(IPA), version 8.7 (http://www.ingenuity.com). The vascu-
lar endothelial growth factor (VEGF) pathway was
observed to have numerous genes with available typed
SNPs and was therefore selected as the source of a subset
of the functional loci for phenotype simulations. The IPA
version of the VEGF signaling pathway was used as the
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Figure 1 Minor allele frequency in the unrelated individuals
sample for the 15,054 SNPs present in multiple copies. Note
that the scale of the MAF categories is uneven, going by 0.5%
intervals for MAF < 0.01, by 1% intervals for MAF = 0.01–0.05, and
by 5% intervals thereafter.
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Page 3 of 9core source because it included most of the genes in the
KEGG VEGF signaling pathway as well as some addi-
tional upstream information, primarily relating to VEGF
transcriptional control. The overlap between the two data
sources was considered significant enough not to impede
the investigations of any researchers limited to the freely
available KEGG data set.
Genes influencing Q1 come primarily from the VEGF
pathway; those influencing Q2 were chosen without
reference to pathways and were primarily related to car-
diovascular disease risk and inflammation, and those
influencing latent disease liability also came primarily
from the VEGF pathway (a different section from the
one in which genes were selected for Q1). Effect sizes
for coding variants within genes were assigned using
PolyPhen and SIFT predictions of the likelihood that the
variant would be deleterious. The functional variants
included both rare and common alleles and a range of
effect sizes, with most having small effects but a few
having large effects that should be reliably detectable in
most replicates of the data set. Some genes contained a
single functional variant and others contained many.
Population origin of the 1000 Genomes Project partici-
pants was not used in the phenotype simulations. In
general, there was little disequilibrium between the
functional variants (Figures 2, 3, 4), with a few excep-
tions that were primarily private variants carried in a
single copy by the same individual (e.g., C3S4836 and
C10S3092 for Q2 and C4S1877 and C4S1889 for Q1).
Quantitative risk factors Q1, Q2, and Q4 were simu-
lated as normally distributed phenotypes. Disease was
simulated using a liability threshold model, and the top
30% of the distribution was declared affected. All SNP
effects were additive on the quantitative trait or liability
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Figure 2 Gametic disequilibrium (r
2) between functional variants for Q1. Markers are shown in chromosomal order from bottom to top
and from left to right and are symmetric across the diagonal.
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Page 4 of 9scale, with each copy of the minor allele increasing the
mean trait value by an equal amount. Genotype by
environment effects were simulated for Q1. Because
genotype, age, and sex were held constant across repli-
cates, the variation in phenotype across replicates came
primarily from the residual polygenic and residual envir-
onmental components. The residual polygenic compo-
nents were correlated between relatives, by definition,
and also correlated between Q1, Q2, and latent liability.
The residual environmental components were unique to
each individual and were simulated to be weakly corre-
lated between Q1, Q2, and latent liability.
Q1
Quantitative risk factor Q1 was influenced by 39 SNPs
in 9 genes (see Table 1). There were 1–11 functional
variants per gene. Their MAFs in the 1000 Genomes
Project data ranged from 0.07% (i.e., a single copy of the
minor allele) to 16.5%. In all cases, the minor allele was
associated with higher mean Q1; the b column in the
table provides the displacement in mean levels of Q1 for
each copy of the minor allele. Q1 also had a residual
heritability of 0.44, resulting from variants at loci not
included in the current sequence data set. The residual
genetic component of Q1 was correlated with the resi-
dual genetic components of Q2 and latent liability.
There were also weaker environmental correlations
between Q1 and Q2 and latent liability. Values of Q1
were higher in smokers, and there was genotype by
smoking interaction for the effects of variants in the
KDR gene on Q1. Effects of the KDR variants were 50%
higher in smokers than in nonsmokers. (Note that for
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Figure 3 Gametic disequilibrium (r
2) between functional variants for Q2. Markers are shown in chromosomal order from bottom to top
and from left to right and are symmetric across the diagonal.
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smokers.) Q1 also increased with age.
Q2
Q2 was influenced by 72 SNPs in 13 genes (see Table 2).
There were 1–13 functional variants per gene. MAFs ran-
ged from 0.07% to 17.07%. In all cases, the minor allele
was associated with higher mean Q2. Q2 had a residual
heritability of 0.29. The residual genetic component of
Q2 was correlated with the residual genetic components
of Q1 and latent liability. There were also weaker envir-
onmental correlations between Q2 and Q1 and latent lia-
bility. Q2 was not influenced by age, sex, or smoking
status.
Q4
Q4 had a heritability of 0.70, but none of this genetic
component was due to genes in this sequencing set (i.e.,
it was not influenced by any of the genotyped exonic
SNPs). Q4 was lower in smokers, decreased with age, and
was lower in females. Q4 was protective; that is, indivi-
duals with higher levels of Q4 had lower risk of disease.
Affection status
A normally distributed latent liability trait (not included
in the distributed phenotype data) was simulated; it was
influenced by 51 SNPs in 15 genes with 1–24 functional
variants per gene (see Table 3). MAFs of these variants
ranged from 0.07% to 25.8%. In all cases, the minor
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Figure 4 Gametic disequilibrium (r
2) between functional variants for latent liability. Markers are shown in chromosomal order from
bottom to top and from left to right and are symmetric across the diagonal.
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Page 6 of 9allele was associated with higher mean liability. This
latent liability trait was also higher in smokers and
increased with age. Disease risk was a function of this
latent liability, Q1, Q2, and Q4:
Liability to disease = latent liability + Q1 + Q2 – Q4. (1)
Using this formula, a quantitative liability score was
calculated for each individual, and the top 30% of the
distribution in each simulation replicate was declared
affected. A consequence of this assignment was that
each replicate had the same number of affected
Table 2 Effects on Q2
Gene SNP MAF b
BCHE C3S4834 0.000717 0.232562
BCHE C3S4836 0.000717 0.352589
BCHE C3S4856 0.000717 0.311344
BCHE C3S4859 0.002152 0.557489
BCHE C3S4860 0.000717 0.339017
BCHE C3S4862 0.000717 0.93321
BCHE C3S4867 0.000717 0.67704
BCHE C3S4869 0.000717 1.15994
BCHE C3S4873 0.002869 0.588113
BCHE C3S4874 0.000717 1.06857
BCHE C3S4875 0.000717 1.15207
BCHE C3S4876 0.000717 0.798247
BCHE C3S4880 0.001435 0.164995
GCKR C2S354 0.012195 0.396642
INSIG1 C7S5132 0.000717 0.0983783
INSIG1 C7S5133 0.000717 0.106056
INSIG1 C7S5144 0.000717 0.237783
LPL C8S442 0.015782 0.490165
LPL C8S476 0.000717 0.725673
LPL C8S530 0.001435 0.800024
PDGFD C11S5292 0.008608 0.60155
PDGFD C11S5299 0.000717 0.823159
PDGFD C11S5301 0.000717 0.982146
PDGFD C11S5302 0.001435 0.814925
PLAT C8S1741 0.003587 0.71858
PLAT C8S1742 0.000717 0.891241
PLAT C8S1758 0.001435 0.86814
PLAT C8S1770 0.000717 0.58405
PLAT C8S1772 0.001435 0.219187
PLAT C8S1773 0.001435 0.515733
PLAT C8S1799 0.005739 0.190653
PLAT C8S1811 0.001435 0.0753783
RARB C3S635 0.000717 0.653224
RARB C3S679 0.005022 0.632142
SIRT1 C10S3048 0.002152 0.825893
SIRT1 C10S3050 0.002152 0.956865
SIRT1 C10S3058 0.000717 0.393157
SIRT1 C10S3092 0.000717 0.352589
SIRT1 C10S3093 0.000717 0.47264
SIRT1 C10S3107 0.000717 0.99946
SIRT1 C10S3108 0.000717 0.52925
SIRT1 C10S3109 0.000717 0.57047
SIRT1 C10S3110 0.002152 0.117719
SREBF1 C17S1007 0.002152 0.548739
SREBF1 C17S1009 0.000717 0.716057
SREBF1 C17S1024 0.004304 0.447239
SREBF1 C17S1030 0.000717 0.734055
SREBF1 C17S1043 0.004304 0.459494
SREBF1 C17S1045 0.003587 0.30998
SREBF1 C17S1046 0.002869 0.604567
SREBF1 C17S1048 0.001435 0.297328
Table 1 Effects on Q1
Gene SNP MAF b
ARNT C1S6533 0.011478 0.589734
ARNT C1S6537 0.000717 0.642689
ARNT C1S6540 0.001435 0.323662
ARNT C1S6542 0.002152 0.488219
ARNT C1S6561 0.000717 0.625721
ELAVL4 C1S3181 0.000717 0.795093
ELAVL4 C1S3182 0.000717 0.328748
FLT1 C13S320 0.001435 0.18047
FLT1 C13S399 0.000717 0.457361
FLT1 C13S431 0.017217 0.732566
FLT1 C13S479 0.000717 0.839669
FLT1 C13S505 0.000717 0.38582
FLT1 C13S514 0.000717 0.549816
FLT1 C13S522 0.027977 0.623466
FLT1 C13S523 0.066714 0.653351
FLT1 C13S524 0.004304 0.596704
FLT1 C13S547 0.000717 0.549214
FLT1 C13S567 0.000717 0.0905862
FLT4 C5S5133 0.001435 0.120761
FLT4 C5S5156 0.000717 0.385374
HIF1A C14S1718 0.000717 0.251622
HIF1A C14S1729 0.002152 0.329088
HIF1A C14S1734 0.012195 0.220448
HIF1A C14S1736 0.000717 0.228202
HIF3A C19S4799 0.000717 0.174668
HIF3A C19S4815 0.000717 0.51468
HIF3A C19S4831 0.000717 0.265181
KDR C4S1861 0.002152 0.598271
KDR C4S1873 0.000717 0.715613
KDR C4S1874 0.000717 0.503025
KDR C4S1877 0.000717 1.17194
KDR C4S1878 0.164993 0.149975
KDR C4S1879 0.000717 0.610938
KDR C4S1884 0.020803 0.318125
KDR C4S1887 0.000717 0.312058
KDR C4S1889 0.000717 1.17194
KDR C4S1890 0.002152 0.417977
VEGFA C6S2981 0.002152 1.13045
VEGFC C4S4935 0.000717 1.40529
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varied across replicates. The effect sizes in Table 3 are
for liability to disease.
Acknowledgments
The Genetic Analysis Workshops are supported by National Institutes of
Health (NIH) grant R01 GM031575. This work was supported in part by NIH
grant R01 MH059490. We are grateful to the 1000 Genomes Project for the
sequence data on which this simulation was based.
This article has been published as part of BMC Proceedings Volume 5
Supplement 9, 2011: Genetic Analysis Workshop 17. The full contents of the
supplement are available online at http://www.biomedcentral.com/1753-
6561/5?issue=S9.
Author details
1Department of Genetics, Texas Biomedical Research Institute, 7620 NW
Loop 410, San Antonio, TX 78245, USA.
2Centro de Investigación en Biología
Molecular y Celular, Universidad de Costa Rica, San José, Costa Rica.
3Menzies Research Institute, 17 Liverpool St (Private Bag 23), Hobart,
Tasmania 7001, Australia.
Authors’ contributions
LA, TDD, and JB designed the phenotypic trait model and the pedigree and
unrelated individuals data sets. JMP aligned and processed sequence data.
JCC and JEC provided input on incorporation of pathway and functional
information and selection of functional variants. TDD conducted the gene
dropping and phenotype simulations. JWK, TDD, LA, and JB performed error
checking on the simulated data. All authors read and approved the final
manuscript.
Competing interests
The authors declare that there are no competing interests.
Table 3 Effects on disease liability
Gene SNP MAF b
AKT3 C1S11396 0.000717 0.340456
BCL2L11 C2S2286 0.000717 0.274592
BCL2L11 C2S2288 0.002869 0.563598
BCL2L11 C2S2307 0.000717 0.606816
ELAVL4 C1S3181 0.000717 0.64359
ELAVL4 C1S3182 0.000717 0.214219
HSP90AA1 C14S3630 0.000717 0.0579258
HSP90AA1 C14S3695 0.000717 0.152617
HSP90AA1 C14S3704 0.003587 0.0789197
HSP90AA1 C14S3706 0.258250 0.0874168
NRAS C1S5748 0.000717 0.409806
PIK3C2B C1S9164 0.001435 0.205094
PIK3C2B C1S9165 0.000717 0.141183
PIK3C2B C1S9172 0.004304 0.508901
PIK3C2B C1S9173 0.001435 0.12026
PIK3C2B C1S9174 0.000717 0.634406
PIK3C2B C1S9189 0.006456 0.454308
PIK3C2B C1S9200 0.000717 0.679158
PIK3C2B C1S9222 0.000717 0.38177
PIK3C2B C1S9250 0.001435 0.358232
PIK3C2B C1S9266 0.002869 0.184476
PIK3C2B C1S9267 0.002152 0.504508
PIK3C2B C1S9306 0.000717 0.239692
PIK3C2B C1S9320 0.000717 0.653693
PIK3C2B C1S9333 0.000717 0.703217
PIK3C2B C1S9346 0.000717 0.29823
PIK3C2B C1S9373 0.000717 0.399922
Table 2 Effects on Q2 (Continued)
SREBF1 C17S1055 0.001435 0.957889
SREBF1 C17S1056 0.000717 0.46384
VLDLR C9S367 0.000717 0.510889
VLDLR C9S376 0.002869 0.543897
VLDLR C9S377 0.001435 1.20543
VLDLR C9S391 0.000717 0.483147
VLDLR C9S430 0.000717 0.677573
VLDLR C9S443 0.001435 0.61953
VLDLR C9S444 0.001435 0.901646
VLDLR C9S497 0.000717 0.731422
VNN1 C6S5378 0.005739 0.466305
VNN1 C6S5380 0.170732 0.248606
VNN3 C6S5412 0.000717 0.551757
VNN3 C6S5426 0.032999 0.110779
VNN3 C6S5439 0.000717 0.127341
VNN3 C6S5441 0.098278 0.268411
VNN3 C6S5446 0.000717 0.528353
VNN3 C6S5448 0.000717 0.581462
VNN3 C6S5449 0.010043 0.680317
VWF C12S181 0.000717 0.76848
VWF C12S211 0.005739 0.337463
Table 3 Effects on disease liability (Continued)
PIK3C2B C1S9391 0.000717 0.582382
PIK3C2B C1S9423 0.000717 0.590111
PIK3C2B C1S9432 0.010760 0.461306
PIK3C2B C1S9445 0.000717 0.582247
PIK3C2B C1S9446 0.000717 0.477664
PIK3C2B C1S9449 0.000717 0.647146
PIK3C2B C1S9455 0.002869 0.518095
PIK3C2B C1S9457 0.000717 0.497112
PIK3C3 C18S2475 0.000717 0.695313
PIK3C3 C18S2492 0.017217 0.576351
PIK3R3 C1S2919 0.000717 0.414798
PRKCA C17S4578 0.166428 0.39334
PRKCA C17S4581 0.000717 0.129034
PRKCB1 C16S1894 0.000717 0.45754
PTK2 C8S4825 0.000717 0.0164796
PTK2 C8S4839 0.000717 0.142502
PTK2B C8S886 0.000717 0.466067
PTK2B C8S900 0.001435 0.111154
PTK2B C8S909 0.001435 0.431062
RRAS C19S4929 0.001435 0.34384
RRAS C19S4937 0.001435 0.462103
SHC1 C1S7061 0.006456 0.206036
SOS2 C14S1381 0.000717 0.613801
SOS2 C14S1382 0.003587 0.633247
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